Drug for heart failure increases mortalityBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7498.981-a (Published 28 April 2005) Cite this as: BMJ 2005;330:981
- David Spurgeon
Patients with heart failure who were treated with the drug nesiritide to help them survive a crisis were 80% more likely to die in the month after treatment than were patients who had received traditional drugs for symptoms of acute heart failure. This was the finding of a US study published last week in JAMA (2005;293: 1900-5).
The drug's manufacturer Scios, which is part of Johnson & Johnson, released …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial